Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension.
Jefferson Antonio BuendiaDiana Guerrero PatinoErika Fernanda LindartePublished in: Expert review of pharmacoeconomics & outcomes research (2023)
Our economic evaluation shows that ambrisentan is not cost-effective regarding bosentan to in treating pulmonary arterial hypertension in C.